Breaking News Instant updates and real-time market news.

MYL

Mylan

$35.94

-0.9 (-2.44%)

16:50
10/07/16
10/07
16:50
10/07/16
16:50

Mylan cuts FY16 adjusted EPS view to $4.70-$4.90 from $4.85-$5.15

Consensus $4.95. The majority of this change in full year 2016 adjusted EPS guidance is the result of the previously announced changes in EpiPen Auto-Injector access programs and the upcoming launch of the generic to EpiPen Auto-Injector. These initiatives seek to further enhance access to, and affordability of, EpiPen Auto-Injector. Much of the impact of this guidance change will occur in the third quarter. Mylan is not providing forward looking guidance for full year 2016 U.S. GAAP EPS guidance or a reconciliation of full year 2016 adjusted EPS to U.S. GAAP EPS because Mylan is unable to predict with reasonable certainty the ultimate outcome of certain significant items without unreasonable effort. These items include, but are not limited to, acquisition-related expenses including those related to the recently closed Meda transaction, restructuring expenses, asset impairments, litigation settlements, changes to contingent consideration and certain other gains or losses. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP EPS for the guidance period.

  • 07

    Oct

  • 28

    Mar

MYL Mylan
$35.94

-0.9 (-2.44%)

09/22/16
ARGS
09/22/16
NO CHANGE
ARGS
Mylan weakness creates good entry point, says Argus
After Mylan's stock fell 17% over the last month, Argus analyst Jacob Kilstein thinks that the stock has reached an attractive entry point, He says that the company's new generic EpiPen will cannibalize branded sales but should help it beat upcoming generic competitors. He thinks that the stock is undervalued and keeps a Buy rating on the stock.
09/23/16
BERN
09/23/16
NO CHANGE
BERN
Mylan generic Epipen to lower EPS by about 10%, says Bernstein
Bernstein analyst Aaron Gal estimates that Mylan's decision to introduce a generic version of its EpiPen will create a drag of about 10% on its EPS. After viewing the Congressional hearings on the device, Gal continues to believe that a competitor to EpiPen will hit the market before the end of 2018. He keeps a $60 price target and Outperform rating on Mylan.
09/30/16
LEER
09/30/16
NO CHANGE
Target $45
LEER
Outperform
Mylan price target cut to $45 on lower EpiPen estimates at Leerink
Leerink analyst Jason Gerberry lowered his EpiPen sales forecasts by 33-45% from 2017-2021 in light of recent company updates, including its plan to launch an authorized generic of the emergency treatment later this year. While Mylan "appears on the right side of the law" regarding the latest Medicaid rebate controversy, Gerberry believes investors should consider the risk of a future settlement related to the issue. He cut his price target on Mylan shares to $45 from $55, but keeps an Outperform rating on the stock as he sees cash flows being sufficient to justify the current price.
10/04/16
JPMS
10/04/16
NO CHANGE
Target $52
JPMS
Overweight
Mylan price target lowered to $52 from $62 at JPMorgan
JPMorgan analyst Chris Schott lowered his price target for Mylan to $52 saying he remains cautious on the shares over the near-term given the ongoing Epipen controversy. The analyst, however, views the stock as "very inexpensive" and keeps an Overweight rating on the name. Schott sees a limited long-term impact to his thesis from the Epipen controversy and believes Mylan's generics business is underappreciated. He maintains an Overweight rating on the shares.

TODAY'S FREE FLY STORIES

MBII

Marrone Bio

$1.75

-0.02 (-1.13%)

08:35
04/25/17
04/25
08:35
04/25/17
08:35
Syndicate
Marrone Bio 5.71M share Spot Secondary priced at $1.40 »

National Securities Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

TBPH

Theravance Biopharma

$39.21

0.42 (1.08%)

08:35
04/25/17
04/25
08:35
04/25/17
08:35
Hot Stocks
Theravance Biopharma presented data from studies of VIBATIV »

Theravance Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

DD

DuPont

$79.37

0.72 (0.92%)

, INTC

Intel

$36.75

0.43 (1.18%)

08:35
04/25/17
04/25
08:35
04/25/17
08:35
Conference/Events
Senate Judiciary Committee to hold a hearing »

The Committee holds a…

DD

DuPont

$79.37

0.72 (0.92%)

INTC

Intel

$36.75

0.43 (1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 31

    May

08:35
04/25/17
04/25
08:35
04/25/17
08:35
General news
Bullish momentum on U.S. equities »

Bullish momentum on U.S.…

IBM

IBM

$160.75

0.37 (0.23%)

, GSK

GlaxoSmithKline

$41.12

0.34 (0.83%)

08:34
04/25/17
04/25
08:34
04/25/17
08:34
Hot Stocks
The Weather Company renews collaboration with GSK Consumer Healthcare »

The Weather Company, an…

IBM

IBM

$160.75

0.37 (0.23%)

GSK

GlaxoSmithKline

$41.12

0.34 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 07

    May

  • 06

    Jun

ECOM

ChannelAdvisor

$11.65

-0.1 (-0.85%)

, EBAY

eBay

$32.05

-0.13 (-0.40%)

08:34
04/25/17
04/25
08:34
04/25/17
08:34
Hot Stocks
ChannelAdvisor announces strategic partnership with eBay »

ChannelAdvisor…

ECOM

ChannelAdvisor

$11.65

-0.1 (-0.85%)

EBAY

eBay

$32.05

-0.13 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 18

    May

MRVL

Marvell

$15.06

0.16 (1.07%)

, AVGO

Broadcom

$221.24

3.58 (1.64%)

08:34
04/25/17
04/25
08:34
04/25/17
08:34
Hot Stocks
Marvell appoints Neil Kim as CTO »

Marvell (MRVL) announced…

MRVL

Marvell

$15.06

0.16 (1.07%)

AVGO

Broadcom

$221.24

3.58 (1.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$45.90

1.81 (4.11%)

08:34
04/25/17
04/25
08:34
04/25/17
08:34
Hot Stocks
Sanofi: Aubagio had significant effect on reducing cortical gray matter atrophy »

Sanofi Genzyme, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

IMMR

Immersion

$8.66

0.18 (2.12%)

08:33
04/25/17
04/25
08:33
04/25/17
08:33
Hot Stocks
Immersion signs multiyear license renewal with ALPS »

Immersion Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$907.41

8.88 (0.99%)

08:33
04/25/17
04/25
08:33
04/25/17
08:33
Periodicals
Amazon opens Amazon Global Selling office in Taiwan, DigiTimes says »

Amazon has opened an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 16

    May

  • 23

    May

PZRX

PhaseRx

$1.91

0.67 (54.03%)

08:33
04/25/17
04/25
08:33
04/25/17
08:33
Hot Stocks
PhaseRx receives 'positive' opinion for orphan drug designation for PRX-OTC »

PhaseRx announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDTX

Cidara Therapeutics

$7.20

0.15 (2.13%)

08:32
04/25/17
04/25
08:32
04/25/17
08:32
Hot Stocks
Cidara Therapeutics promotes Taylor sandison to chief medical officer »

Cidara Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DMPI

DelMar Pharmaceuticals

$2.70

-0.1 (-3.57%)

08:32
04/25/17
04/25
08:32
04/25/17
08:32
Hot Stocks
DelMar Pharma enters into collaboration with Duke University for VAL-083 »

DelMar Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSIS

OSI Systems

$72.27

0.63 (0.88%)

08:31
04/25/17
04/25
08:31
04/25/17
08:31
Hot Stocks
OSI Systems awarded $7M contract to provide checkpoint inspection systems »

OSI Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 06

    Jun

BNED

Barnes & Noble Education

$10.38

0.08 (0.78%)

08:31
04/25/17
04/25
08:31
04/25/17
08:31
Hot Stocks
Barnes & Noble Education names Michael Miller chief legal officer »

Barnes & Noble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

08:31
04/25/17
04/25
08:31
04/25/17
08:31
Options
One option delisting on April 25th »

Option delistings…

LLY

Eli Lilly

$83.42

1.53 (1.87%)

08:30
04/25/17
04/25
08:30
04/25/17
08:30
Technical Analysis
Eli Lilly trades lower after earnings and outlook »

The shares were last…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

  • 07

    May

  • 31

    May

BIDU

Baidu

$180.03

1.95 (1.10%)

, NFLX

Netflix

$143.83

0.96 (0.67%)

08:28
04/25/17
04/25
08:28
04/25/17
08:28
Technical Analysis
Netflix edges up to 52-week highs in pre-market trading »

Shares were last at…

BIDU

Baidu

$180.03

1.95 (1.10%)

NFLX

Netflix

$143.83

0.96 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 05

    Jun

ANTM

Anthem

$168.41

0.61 (0.36%)

, ESRX

Express Scripts

$67.25

0.79 (1.19%)

08:28
04/25/17
04/25
08:28
04/25/17
08:28
Recommendations
Anthem, Express Scripts analyst commentary  »

Anthem contract…

ANTM

Anthem

$168.41

0.61 (0.36%)

ESRX

Express Scripts

$67.25

0.79 (1.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 18

    May

  • 06

    Jun

WAT

Waters

$160.27

1.75 (1.10%)

08:26
04/25/17
04/25
08:26
04/25/17
08:26
Earnings
Waters sees FY17 EPS $7.20-$7.40, consensus $7.04 »

Sees a mid single digit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

AAPL

Apple

$143.64

1.37 (0.96%)

, CBS

CBS

$65.95

-0.89 (-1.33%)

08:25
04/25/17
04/25
08:25
04/25/17
08:25
Periodicals
Apple Music delays release of first series 'Carpool Karaoke,' Reuters reports »

Apple's Apple Music…

AAPL

Apple

$143.64

1.37 (0.96%)

CBS

CBS

$65.95

-0.89 (-1.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 04

    May

  • 15

    Jun

WAT

Waters

$160.27

1.75 (1.10%)

08:25
04/25/17
04/25
08:25
04/25/17
08:25
Earnings
Waters sees Q2 EPS $1.65-$1.75, consensus $1.67 »

Sees strong mid-single…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

08:25
04/25/17
04/25
08:25
04/25/17
08:25
Conference/Events
The Washington Journal holds a discussion on Dodd-Frank »

Manhattan Institute…

WHR

Whirlpool

$174.80

3.29 (1.92%)

08:22
04/25/17
04/25
08:22
04/25/17
08:22
Hot Stocks
Whirlpool sees 3%-5% annual organic net sales growth, 10%+ EBIT margin by 2020 »

Says fundamentals of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

$DJT

DJ Transportation Average

08:21
04/25/17
04/25
08:21
04/25/17
08:21
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.